|
WO2015168555A1
|
|
Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
|
|
WO2015168587A1
|
|
Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds
|
|
CN105960239A
|
|
Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
|
|
WO2015078931A1
|
|
Method of treating neuroblastomas using thienotriazolodiazepine compounds
|
|
WO2015018523A1
|
|
A novel bet-brd inhibitor for treatment of solid tumors
|
|
WO2015018520A1
|
|
A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
|
|
WO2015018522A1
|
|
Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
|
|
CN106029077A
|
|
Pharmaceutical formulation containing thienotriazolodiazepine compounds
|
